key: cord-0847225-95ab9052
authors: Yang, Mei; Cao, Shuang; Liu, Yong; Zhang, Zhijie; Zheng, Rui; Li, Yuzhong; Zhou, Jie; Zong, Chengguo; Cao, Desheng; Qin, Xiaosong
title: Performance Verification of Five Commercial RT-qPCR Diagnostic Kits for SARS-CoV-2
date: 2021-12-10
journal: Clin Chim Acta
DOI: 10.1016/j.cca.2021.12.004
sha: ba2624674714795f97b23c5107a9a1fd76e28f0d
doc_id: 847225
cord_uid: 95ab9052

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused a global pandemic beginning in 2020, can be detected by reverse-transcription polymerase chain reaction (RT-PCR). However, owing to the urgent need for a large number of detection kits, the time spent researching and developing these kits has been shortened during the pandemic, and the kits that are being used commercially have not undergone full and independent evaluation. To ensure the accuracy of SARS-CoV-2 test results, performance verification of commercial Real-Time quantitative PCR (RT-qPCR) kits is required. METHODS: The performance of five commercial RT-qPCR diagnostic kits for SARS-CoV-2 used in China was evaluated using a coronavirus disease 2019 (COVID-19) RNA liquid performance verification reference product—manufactured by Guangzhou Bondson (BDS) Biotechnology Co., Ltd.,Guangzhou, China—that uses droplet digital RT-PCR technology combined with fluorescence quantitative PCR. The five kits of Novel Coronavirus 2019-nCoV nucleic acid detection kit (RT-qPCR method) evaluated were Da An (Da An Gene Co., Ltd. of Sun Yat-sen University), Liferiver (Shanghai ZJ Bio-Tech Co., Ltd.), Kinghawk (Beijing Kinghawk Pharmaceutical Co., Ltd.), eDiagnosis (Wuhan Easy Diagnosis Biomedicine Co., Ltd.), and Maccura (Maccura Biotechnology Co., Ltd.). Performance verification criteria included the coincidence rate, limit of detection (LoD), cross-reactivity, precision, and anti-interference. Finally, through the BDS performance verification reference product kit, clinical samples are used to verify its clinical diagnostic efficacy. RESULTS: The coincidence rate was 100% for all kits except for Kinghawk, which was 95%. The LoD for Da An, eDiagnosis and Maccura was 250copies/mL, and it was 1000 copies/ml for Liferiver. Kinghawk was not able to detect its advertised LoD of 500 copies/ml. The cross-reactivity test results were all negative. Moreover, all kits had a coefficient of variation less than 5%; however, Liferiver showed the best precision. Da An, Liferiver, and eDiagnosis showed higher sensitivity to the nucleocapsid (N) gene than they did to the open reading frame (ORF) 1ab genes. Anti-interference results for all five kits were positive. The results of clinical diagnostic efficacy were that the specificity of the four kits was 1.000 (0.877-1.000), the sensitivity of Da An was 1.000 (0.850-1.000), Liferiver was 0.964 (0.798-0.998), Maccura was 0.893 (0.706-0.972), and eDiagnosis was 0.857 (0.664-0.953). CONCLUSIONS: Except for Kinghawk, all commercial RT-qPCR diagnostic kits for SARS-CoV-2 passed the BDS performance verification. Da An and Liferiver have excellent clinical diagnostic specificity and sensitivity. This study can provide guidance for the selection or optimization of RT-qPCR diagnostic test kits for SARS-CoV-2.

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; a novel coronavirus) in December 2019 is responsible for the coronavirus disease 2019 (COVID-19) pandemic [1] . SARS-CoV-2 is an enveloped RNA virus that belongs to the genus β-coronavirus. The coronavirus open reading frame (ORF), nucleocapsid (N) protein, and envelope (E) protein genes are the most commonly used targets for the detection of SARS-CoV-2 [2] . SARS-CoV-2 infection is highly contagious and can spread through respiratory droplets, aerosols, contact, and feces [3] . As of December 2, 2021, COVID-19 has spread to more than 192 countries and regions, with more than 264.13 million confirmed cases and 5.23 million deaths worldwide(https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda75 94740fd40299423467b48e9ecf6). COVID-19 has also caused unpredictable economic losses. Hence, there is an urgent need for a fast, sensitive, and inexpensive detection method to identify SARS-CoV-2 infection and ultimately curb the development and spread of COVID-19 [4] .

RT-qPCR can measure the amount of viral RNA in real-time and is considered the gold standard for SARS-CoV-2 detection [5] . In the Seventh Edition of China's New Coronary Diagnosis and Treatment Guidelines, one of the diagnostic criteria for COVID-19 is a positive RT-qPCR result, and one of the discharge criteria is that respiratory tract specimens should yield two consecutive negative SARS-CoV-2 test results [6] . Therefore, nucleic acid detection of SARS-CoV-2 is important for proper diagnosis and for appropriate handling of patients. Unfortunately, this technology also has a false negative rate that cannot be ignored [7, 8] . Sensitivity is affected by multiple factors, including the inherent characteristics of the selected patient, such as disease stage and viral load, method of collection, sample management, and performance of the test kits used [9, 10] . Among these, evaluating the performance of different test kits could greatly help identify the cause of false negatives [11] .

Currently, there are several different SARS-CoV-2 RT-qPCR kits that fully serve the needs for prevention and control of the COVID-19 pandemic and provide an important guarantee for the diagnosis of COVID-19. However, owing to the urgent need for diagnostic kits, research and development related to nucleic acid detection kits for SARS-CoV-2 have been hastened, resulting in issues such as the conducting of clinical trials that are too small-scaled, insufficient scientific data support, and the use of commercial nucleic acid detection kits that have not been fully and independently evaluated. In this study, using the new coronavirus ribonucleic acid (COVID-19 RNA) liquid performance verification RT-PCR reference product (Guangzhou Bondson Biotechnology Co., Ltd., Guangzhou, China) as a reference, we evaluated the performance of five commercial RT-PCR diagnostic kits for SARS-CoV-2. This study provides a reference for clinical laboratories for selecting the SARS-CoV-2 nucleic acid detection kits to be used.

We used the COVID-19 RNA liquid performance verification reference product BDS (Guangzhou Bondson Biotechnology Co. Ltd.; batch number 2020001) that is based on the SARS-CoV-2 pseudovirus culture medium containing the important characteristic SARS-CoV-2 genes, namely, the full-length N, E, and ORF1ab genes. Table 1 .

The Stream SP96 automatic nucleic acid extraction instrument (Da An Gene Co., Ltd. of Sun Yat-sen University) was used for nucleic acid extraction. RT-qPCR was conducted using the SLAN-96P real-time PCR system (Shanghai Hongshi Biotechnology Co., Ltd., Shanghai, China).

The RT-qPCR cycle parameters were set according to the kit instructions. The baseline was usually automatically set by the instrument. The baseline adjustment principle included selecting the area with a stable fluorescence signal before exponential amplification, avoiding signal fluctuation at the beginning of fluorescence acquisition, and reducing the threshold cycle (Ct)/quantification cycle (Cq) value of the sample with the earliest exponential amplification by 1-2 cycles at the end. The principle of setting threshold line is to make the threshold line in the exponential phase of amplification curve. RT-qPCR data are traditionally analyzed by estimating the Ct in which the fluorescent signal generated by the probe emission crosses the threshold line. Refer to the instructions of the corresponding kits for the baseline and threshold settings. Here, the negative and positive test results were judged according to the specific kit instructions.

There were 10 positive reference samples in BDS, numbered P1-P10, and 10 negative patient samples from previous tests, numbered P11-P20, totaling 20 samples. Nucleic acid extraction was carried out using a Da An nucleic acid extraction kit ( Da An Gene Co., Ltd. of Sun Yat-sen University). Amplification was performed using the five commercial RT-qPCR diagnostic kits for SARS-CoV-2 as mentioned above, using the same Hongshi SLAN-96P real-time PCR system (Shanghai Hongshi Biotechnology Co., Ltd., Shanghai, China). A kit was considered to have passed verification if the coincidence rate of negative and positive results was ≥95%.

The concentrations of the limit of detection (LoD) reference products L1-L5 provided in BDS were 200,000, 20,000, 2,000, 500, and 250 copies/ml, respectively. Detection was performed 3 times for each sample, and the lowest concentration at which all three results were positive was considered as the initial screening LoD.

Then, detection at the LoD was performed for each sample 20 consecutive times in different batches (five batches were tested, and the test was repeated four times for each batch) for statistical analysis. The lowest concentration level, with a detection rate of 100% positive results, was taken as the LoD for each kit.

Twenty analysis-specific reference samples, N1-N20, were included in BDS (Table 2 ). Nucleic acid extraction was performed using the Da An kit and then amplification was carried out using the five commercial RT-qPCR diagnostic kits for SARS-CoV-2 with the same amplification instrument. Each sample was tested three times. To pass in terms of cross-reactivity, all results should be negative for cross-reactivity.

The precision reference products in BDS include low concentration (R1, 2,000 copies/mL) and medium concentration (R2, 20,000 copies/mL) products. The five commercial RT-qPCR diagnostic kits for SARS-CoV-2 were used for amplification using the same amplification instrument. One batch was measured per day for 5 d, and the measurement of each batch was repeated four times. Thus, 20 measurements were taken at each concentration. Precision verification was considered passed if the precision coefficient of variation (CV) value was <5%.

The ability of the five commercial kits to detect SARS-CoV-2 in interference reference samples I1-I3 (that contained 30 g/dL hemoglobin, 6 g/dL albumin, and 100 µg/mL ribavirin and azithromycin for 2,000 copies/mL positive samples) was assessed. The concentration of the positive samples in the interfering substance was considered to be a weak positive concentration, which was set based on 2-5x the LoD of the kits on the market. The concentration of interference was set according to the anti-interference ability of the kit. The detection of each sample was performed in three replicates for each commercial kit. If the three replicates were positive, the results were positive, then that particular kit was considered to pass the anti-interference verification. Diego, CA, USA) were used for statistical analyses. The Mann-Whitney U-test was employed for comparisons between two groups. The Kruskal-Wallis test was used to compare three independent groups. A P-value < 0.05 was considered significant. In order to evaluate the detection efficiency and diagnostic value of the RT-qPCR kits, we calculated the sensitivity, specificity, PPV, NPV and its 95% confidence interval (CI). 

The coincidence rate for all five diagnostic kits was 100%, except for Kinghawk.

One of the 10 positive reference products was not detected by Kinghawk, while all 10 negative reference products yielded negative results. Hence, the Kinghawk coincidence rate was 95% (Table 3) . 

Kinghawk failed to detect the initial screening concentration of 1,000 copies/mL, even after repeating the test. The preliminary screening LoD of Liferiver was 500 copies/mL, while that of Da An, eDiagnosis, and Maccura was 250 copies/mL in each case ( Figure 1 ). Moreover, it was observed that as the concentration of the reference product decreased, the Ct value gradually increased ( Figure 1 ). The confirmed LoD of Liferiver was 1,000 copies/mL and that of Da An, eDiagnosis, and Maccura was 250 copies/mL ( Figure S1 ). Since ≥100% of the positive results met expectations, the kits passed verification. The LoD of Da An, eDiagnosis, and Maccura was 250 copies/mL and for Liferiver it was 1,000 copies/mL, indicating that these four kits met their respective declared LoD. Meanwhile, Kinghawk did not meet the LoD of 500 copies/mL declared by its manufacturer. It is also worth noting that the values of the verification results of the LoD of Da An, eDiagnosis, and Maccura (250 copies/mL) were lower than those declared by their respective manufacturer (500copies/mL, 500copies/mL and 1,000 copies/mL). 

The list of the specific pathogenic microorganisms used to assess the cross-reactivity of each diagnostic test kit is shown in Table 2 . All test results for cross-reactivity were negative, indicating that the five commercial RT-qPCR diagnostic test kits for SARS-CoV-2 had strong specificity and that the presence of the pathogenic microorganisms listed in Table 2 would not affect the ability of the test kits to detect SARS-CoV-2.

The precision of the five commercial RT-qPCR diagnostic kits for SARS-CoV-2 was in line with that declared by their respective manufacturers (<5% CV, Table 4 ).

The distribution of Ct values of 20 test results of each commercial RT-qPCR diagnostic test kit for SARS-CoV-2 are shown in Figure 2 . As illustrated, Liferiver had the smallest CV for ORF1ab gene detection in reference product R1 (1.05%; Fig. 2F ). Therefore, the sensitivity of Da An, Liferiver, and eDiagnosis for the N gene was higher than that for the ORF1ab gene at both low and median concentrations of the reference product. 

The anti-interference test results showed that all five commercial RT-qPCR diagnostic kits for SARS-CoV-2 were able to detect ORF1ab and N genes in the I1-I3 samples, indicating that 30 g/dL hemoglobin, 6 g/dL albumin, and 100 µg/mL ribavirin and azithromycin, respectively, did not interfere with SARS-CoV-2 nucleic acid detection. Moreover, the five test kits showed no statistical differences in the detection of the ORF1ab and N genes in the I1-I3 samples ( Figure 3A , 3B). g/dL albumin, and 100 µg/mL ribavirin and azithromycin, respectively.

We evaluated the clinical diagnostic efficacy of the four RT-qPCR kits that have passed the BDS performance verification reference product: Da An, Liferiver, eDiagnosis, and Maccura, and the results are shown in Table 5 . The specificity of all the four kits was 1.000 (0.877-1.000). Da An has the highest sensitivity of 1.000 

The rapid and accurate detection of SARS-CoV-2 plays a key role in determining the treatment plan for COVID-19 patients and for controlling the spread of infection [12] . RT-qPCR has a high sensitivity and specificity; therefore, it is currently used as the main method for COVID-19 diagnosis [13] . Thus, when SARS-CoV-2 nucleic acid detection is the gold standard for COVID-19 diagnosis, the sensitivity and accuracy of the diagnostic test kits are particularly important. Under normal circumstances, it takes 3-5 years to obtain a registration certificate for nucleic acid kits, during which the kit needs to be continuously optimized and verified with a large number of clinical samples. Inevitably, there are some flaws in the quality and performance parameter settings of many commercial kits, and manufacturers are constantly updating and optimizing their kits. One of these flaws is that the LoD advertised by manufacturers is based on the best extraction method and best experimental conditions before the test kit leaves the factory; there is often a lack of clinical verification data in such scenarios. Therefore, when performing SARS-CoV-2 nucleic acid testing, the laboratory, clinician, or end-user should first evaluate the performance of the test kit [11] . [16, 17] . Accupower (bioner, South Korea) had a sensitivity of 75.5%, and its limit of detection estimated to be bigger than 20000 copies/mL and was not authorized by the FDA or EUA [18] . Allplex (Seegene, South Korea) and

Viasure (CerTest Biotec, Spain) had high sensitivities of 96.5% and 91.9%, respectively, and limit of detection of 4000 copies/mL and 2000 copies/mL [18, 19] .

Through the performance verification of the above kits, we can see that some kits fail to pass the performance verification. 

Owing to the urgent need for a large number of SARS-CoV-2 detection kits, the time spent researching and developing these kits has been shortened during the pandemic, and the kits that are being used commercially have not undergone full and independent evaluation. To ensure the accuracy of SARS-CoV-2 test results, performance verification of commercial RT-qPCR kits is required. (0.850-1.000), followed by Liferiver, and eDiagnosis has the lowest sensitivity of 0.857 (0.664-0.953). This study provides a reference for clinical laboratories for selecting the SARS-CoV-2 nucleic acid detection kits to be used, helps manufacturers to optimize kits and also provides laboratory methods for clinical laboratories to verify the performance of SARS-CoV-2 kits.

The study was conducted in accordance with the International Coordinating Council for Clinical Trials and the Helsinki Declaration and was approved by the Hospital Ethics Review Committee (Ethics No 2020PS038K). Informed consent from patients was exempted.

China Novel Coronavirus, T. Research, A Novel Coronavirus from Patients with Pneumonia in China

Comparison of seven commercial RT-PCR diagnostic kits for COVID-19

China Medical Treatment Expert Group for, Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets

National Health Commission of the People's Republic of China. Diagnosis and Treatment Protocol for COVID-19

Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR

Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease

Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19

Potential False-Negative Nucleic Acid Testing Results for Severe Acute Respiratory Syndrome Coronavirus 2 from Thermal Inactivation of Samples with Low Viral Loads

Evaluation of the clinical performance of single-, dual-, and triple-target SARS-CoV-2 RT-qPCR methods

Recent advances in the detection of respiratory virus infection in humans

On Behalf Of, N. Erli, Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries

Evaluation of nCoV-QS (MiCo BioMed) for RT-qPCR detection of SARS-CoV-2 from nasopharyngeal samples using CDC FDA EUA qPCR kit as a gold standard: An example of the need of validation studies

Analytical and Clinical Evaluation of Two RT-qPCR SARS-CoV-2 Diagnostic Tests with Emergency Use Authorization in Ecuador

Low clinical performance of the Isopollo COVID-19 detection kit (M Monitor, South Korea) for RT-LAMP SARS-CoV-2 diagnosis: A call for action against low quality products for developing countries

Poor sensitivity of "AccuPower SARS-CoV-2 real time RT-PCR kit (Bioneer, South Korea)

AccuPower SARS-CoV-2 Multiplex RT-PCR kit (Bioneer, South Korea)" and "Allplex 2019-nCoV Assay (Seegene, South Korea)" for SARS-CoV-2 RT-PCR Diagnosis: Korean CDC EUA as a Quality Control Proxy for Developing Countries

RT-qPCR kits for SARS-CoV2 diagnosis

Evaluation of Four Commercial Kits for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved by Emergency-Use-Authorization in Korea

Assessment of 12 qualitative RT-PCR commercial kits for the detection of SARS-CoV-2

Limits of Detection of 6 Approved RT-PCR Kits for the Novel SARS-Coronavirus-2 (SARS-CoV-2)

Clinical Performance and Analytical Sensitivity of Three SARS-CoV-2 Nucleic Acid Diagnostic Tests

Confirmation test results of the limit of detection of four commercial RT-qPCR diagnostic test kits for SARS-CoV-2 evaluated in this study. The baseline and threshold were usually automatically set by the instrument according to kit instructions (n=20)

Kinghawk was not able to detect its advertised LoD of 500 copies/mL. 2. Except for Kinghawk, all commercial RT-PCR diagnostic kits for SARS-CoV-2 passed the BDS performance verification

Da An and Liferiver have excellent clinical diagnostic specificity and sensitivity

All authors have accepted responsibility for the entire content of this manuscript and approved its submission. 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

All authors have accepted responsibility for the entire content of this manuscript and approved its submission.The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.